HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dass, C.R. Articles by Choong, P.F.M. Search for Related Content PubMed PubMed Citation Articles by Dass, C.R. Articles by Choong, P.F.M.

Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics

¹ Department of Orthopaedics, University of Melbourne, St. Vincent’s Health, P.O. Box 2900, Fitzroy, 3065, Melbourne, Australia; and
² Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, Australia

^* corresponding author, crispin.dass{at}svhm.org.au

Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.

KEY WORDS: angiogenesis • therapy • blood vessel • cancer • vasculature

This article has been cited by other articles:

				J. Dai and A.B.M. Rabie VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification J. Dent. Res., October 1, 2007; 86(10): 937 - 950. [Abstract] [Full Text] [PDF]